| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| ln Vitro |
Atezolizumab-MMAE (compound 3) (4 µg/mL, 0.5–24 hours) can bind to the PD-L1 antigen on the cell membrane of MDA-MB-231 cells and be internalized and transported to lysosomes within 30 minutes [1]. Atezolizumab-MMAE (0.725–200,000 pmol/L, 3 days) has potent tumor cell inhibitory activity (EC50 values of 10.33, 9.75, and 11.94 nM for PD-L1 positive MDA-MB-231, PC 9, and A431 cells, respectively), but has a weaker effect on PD-L1 negative Romas cells (EC50: 129.4 nM) [1]. Atezolizumab-MMAE (0.625-10 μg/mL, 48 h) can inhibit the interaction between PD1 and PD-L1 and significantly increase the level of IFN-γ when co-cultured with PBMC[1].
|
|---|---|
| ln Vivo |
In the MC38 xenograft PD-1 humanized immune system mouse model, Atezolizumab-MMAE (compound 3) (3 mg/kg, intraperitoneal injection, twice a week for 3 weeks) showed strong antitumor activity (tumor inhibition rate of 68% and tumor regression rate of 60%) compared with Atezolizumab alone [1].
|
| Cell Assay |
Cell viability assay [1]
Cell Types: MDA-MB-231, PC 9, A431, Romas cells Tested Concentrations: 0.725-200000 pmol/L Incubation Duration: 3 days Experimental Results: The cells showed strong inhibitory activity against MDA-MB-231, PC 9, and A431 PD-L1+ cell lines, with EC50 values of 10.33 nM, 9.75 nM, and 11.94 nM, respectively. The cells showed weak inhibitory activity against the PD-L1- cell line Romas, with an EC50 value of 124.9 nM. Cell viability assay [1] Cell Types: MDA-MB-231 cells Tested Concentrations: 4 µg/mL Incubation Duration: 0, 0.5, 1, 4, 18, 24 hours Experimental Results: The cells can bind to the PD-L1 antigen on the cell membrane of MDA-MB-231 at 4 °C. They can be inoculated into the lysosomes of MDA-MB-231 cells in just 30 minutes. |
| Animal Protocol |
Animal/Disease Models:MC38 cells in logarithmic growth phase (1 × 10⁶ cells/mouse)[1] were subcutaneously inoculated into the groin of the lateral hind limb of 6-8 week old female C57BL/6J-Pdcd1em1 (hPDCD1)/Smoc mice.
Doses: 3 mg/kg Route of Administration: Intraperitoneal injection, twice a week for 3 weeks until the tumor volume reached approximately 50-150 mm³, after which tumor volume and body weight were measured twice a week. Experimental Results: Significant and sustained antitumor effect was observed, with a tumor inhibition rate of 68%. Tumors shrank significantly, with a tumor regression rate of 60%, higher than that of atezolizumab alone (tumor regression rate: 40%). The safety profile was good, with no significant changes in body weight observed. |
| References |
|
| Appearance |
Liquid
|
|---|---|
| SMILES |
[Atezolizumab-MMAE]
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: 本产品在运输和储存过程中需避光（避免光照）。 |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
